期刊文献+
共找到359篇文章
< 1 2 18 >
每页显示 20 50 100
Establishment of Monoclonal Antibody Competitive ELISA Using Monoclonal Antibody Against VP1 Protein of Asia 1 Type Foot-and-Mouth Disease Virus 被引量:4
1
作者 林彤 邵军军 +4 位作者 丛国正 独军政 高闪电 常惠芸 谢庆阁 《Agricultural Science & Technology》 CAS 2009年第3期104-107,共4页
Using the purified VP1 protein of Asia 1 type foot-and-mouth disease virus as the antigen, the purified monoclonal antibody was labeled by the sodium periodate method and the monoclonal antibody competitive ELISA was ... Using the purified VP1 protein of Asia 1 type foot-and-mouth disease virus as the antigen, the purified monoclonal antibody was labeled by the sodium periodate method and the monoclonal antibody competitive ELISA was established in this study. Ten positive porcine foot-and-mouth disease serums and more than two hundreds negative serum were tested, and the results were the same as the background of samples. The sensitivity test and replicate test indicated that this method was stable and sensitive, which was suitable for monitoring Asia 1 type porcine foot-and-mouth disease virus antibody. 展开更多
关键词 Asia 1 FMDV VP1 monoclonal antibody Competitive ElISA
下载PDF
Analysis of Specific Th1/Th2 Helper Cell Responses and IgG Subtype Antibodies in Anti-CD4 Monoclonal Antibody Treated Mice with Autoimmune Cardiomyopathy
2
作者 汪朝晖 廖玉华 +3 位作者 袁璟 张景辉 董继华 王金平 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 2008年第4期409-414,共6页
The cytokine repertoire of ADP/ATP carrier-specific humoral immune responses and the cytokine-dependent anti-ADP/ATP carrier antibody IgG subclasses were examined in a cohort of ADP/ATP carrier-immunized BALB/c mice t... The cytokine repertoire of ADP/ATP carrier-specific humoral immune responses and the cytokine-dependent anti-ADP/ATP carrier antibody IgG subclasses were examined in a cohort of ADP/ATP carrier-immunized BALB/c mice treated with anti-CD4 monoclonal antibody. Eighteen male BALB/c mice (6–8 weeks old) were randomized into 3 groups: dilated cardiomyopathy (DCM) group, DCM-tolerance (Tol) group and control group. The mice in DCM group were immunized with the peptides derived from human ADP/ATP carrier protein for 6 months and mice in the control group were sham-immunized, while the mice in DCM-Tol group were immunized with ADP/ATP carrier protein and anti-CD4 McAb simultaneously. Serum autoantibody against ADP/ATP carrier and IgG subclasses were measured by ELISA, intracellular cytokines IFN-γ and IL-4 of Th cells were moni- tored with flow cytometry, and splenic T cell cytokines IFN-γ, IL-2, IL-4 and IL-6 were detected by using real-time fluorescent quantitative PCR. The results showed that the autoantibody against ADP/ATP carrier was found in all mice in DCM group, and the antibody level, serum IgG1 and IgG2a subclasses, cytokines in T cells and Th cells were all elevated in DCM group, as compared with those in control group (P〈0.01). On the other hand, in DCM-Tol group, the autoantibody level and contents of all the cytokines were significantly different from those in DCM group (P〈0.01), and were close to those in control group. And the levels of IgG1, IgG2a, IgG2b and IgG3 were influenced, to varying degrees, by anti-CD4 McAb as compared with those in DCM group. All these four types of IgG subclasses were substantially decreased in DCM-Tol group as compared with DCM group. It is concluded that the treatment with anti-CD4 McAb could prevent the activation of T cells, reverse the abnormal secretion of cytokines and the imbalance between Th1/Th2 cell subsets and abnormal production of autoantibody against ADP/ATP carrier, and eventually avoid myocardial injuries. 展开更多
关键词 CD4 monoclonal antibody AUTOIMMUNITY Th1/Th2 immune response ADP/ATP carrier peptides
下载PDF
血清IL-17、INF-γ水平与肝细胞癌患者PD-1单抗治疗效果的关系
3
作者 徐凌翔 涂兵 《中国医药指南》 2024年第17期34-36,共3页
目的探究血清IL-17、INF-γ水平与肝细胞癌患者PD-1单抗治疗效果的关系。方法选取2023年1月至2023年8月收治的60例肝细胞癌患者作为研究对象,均接受PD-1单抗治疗。比较观察治疗有效患者与无效患者IL-17、INF-γ水平情况,IL-17、INF-γ... 目的探究血清IL-17、INF-γ水平与肝细胞癌患者PD-1单抗治疗效果的关系。方法选取2023年1月至2023年8月收治的60例肝细胞癌患者作为研究对象,均接受PD-1单抗治疗。比较观察治疗有效患者与无效患者IL-17、INF-γ水平情况,IL-17、INF-γ水平与肝癌细胞患者各临床特征的关系,ROC曲线分析IL-17、INF-γ表达水平对肝癌细胞患者PD-1单抗治疗效果的预测价值关系。结果治疗有效组患者IL-17水平(14.17±2.08)pg/ml低于治疗无效组的(21.28±3.69)pg/ml,INF-γ(37.45±4.52)pg/ml高于对照组的(22.36±3.27)pg/ml(P<0.05)。在临床分期、肝外转移、血管侵犯等方面,分期越高、有肝外转移、有血管侵犯患者的IL-17水平高于分期越低、无肝转移、无血管侵犯患者(P<0.05)。分期越高、有肝外转移、有血管侵犯患者的INF-γ水平低于分期越低、无肝外转移、无血管侵犯患者(P<0.05)。通过ROC曲线的绘制可以得出:(1)IL-17、INF-γ的曲线下面积分别是0.753、0.764,均具有良好的诊断效能,但与2项联合相比,2项联合的曲线下面积0.877均高于各单一指标的曲线下面积(P<0.05);(2)IL-17、INF-γ的cut-off值是6.21 pg/ml、36.52 pg/ml;(3)2项联合的灵敏度(0.935)、特异度(0.952)均明显高于IL-17的(0.552、0.801)和INF-γ的(0.457、0.824)(P<0.05)。结论血清IL-17、INF-γ水平可对细胞癌患者PD-1单抗治疗效果进行预测评估,且两者联合预测的效能更高,具有显著的临床应用价值。 展开更多
关键词 肝细胞癌 白细胞介素17 PD-1单抗 疗效
下载PDF
IMpower210:A phase Ⅲ study of second-line atezolizumab vs. docetaxel in East Asian patients with non-small cell lung cancer
4
作者 Yi-Long Wu Shun Lu +11 位作者 Gongyan Chen Jianxing He Jifeng Feng Yiping Zhang Liyan Jiang Hongming Pan Jianhua Chang Jian Fang Amy Cai Lilian Bu Jane Shi Jinjing Xia 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2024年第2期103-113,共11页
Objective: IMpower210(NCT02813785) explored the efficacy and safety of single-agent atezolizumab vs.docetaxel as second-line treatment for advanced non-small cell lung cancer(NSCLC) in East Asian patients.Methods: Key... Objective: IMpower210(NCT02813785) explored the efficacy and safety of single-agent atezolizumab vs.docetaxel as second-line treatment for advanced non-small cell lung cancer(NSCLC) in East Asian patients.Methods: Key eligibility criteria for this phase Ⅲ, open-label, randomized study included age ≥18 years;histologically documented advanced NSCLC per the Union for International Cancer Control/American Joint Committee on Cancer staging system(7th edition);Eastern Cooperative Oncology Group performance status of 0 or 1;and disease progression following platinum-based chemotherapy for advanced or metastatic NSCLC. Patients were randomized 2:1 to receive either atezolizumab(1,200 mg) or docetaxel(75 mg/m^(2)). The primary study endpoint was overall survival(OS) in the intention-to-treat(ITT) population with wild-type epidermal growth factor receptor expression(ITT EGFR-WT) and in the overall ITT population.Results: Median OS in the ITT EGFR-WT population(n=467) was 12.3 [95% confidence interval(95% CI),10.3-13.8] months in the atezolizumab arm(n=312) and 9.9(95% CI, 7.8-13.9) months in the docetaxel arm[n=155;stratified hazard ratio(HR), 0.82;95% CI, 0.66-1.03]. Median OS in the overall ITT population was 12.5(95% CI, 10.8-13.8) months with atezolizumab treatment and 11.1(95% CI, 8.4-14.2) months(n=377) with docetaxel treatment(n=188;stratified HR, 0.87;95% CI, 0.71-1.08). Grade 3/4 treatment-related adverse events(TRAEs) occurred in 18.4% of patients in the atezolizumab arm and 50.0% of patients in the docetaxel arm.Conclusions: IMpower210 did not meet its primary efficacy endpoint of OS in the ITT EGFR-WT or overall ITT populations. Atezolizumab was comparatively more tolerable than docetaxel, with a lower incidence of grade3/4 TRAEs. 展开更多
关键词 Atezolizumab East Asia non-small cell lung cancer programmed death-ligand 1 inhibitors monoclonal antibody
下载PDF
Evaluation of teplizumab's efficacy and safety in treatment of type 1 diabetes mellitus:A systematic review and meta-analysis
5
作者 Xiao-Lan Ma Dan Ge Xue-Jian Hu 《World Journal of Diabetes》 SCIE 2024年第7期1615-1626,共12页
BACKGROUND Islets of Langerhans beta cells diminish in autoimmune type 1 diabetes mellitus(T1DM).Teplizumab,a humanized anti-CD3 monoclonal antibody,may help T1DM.Its long-term implications on clinical T1DM developmen... BACKGROUND Islets of Langerhans beta cells diminish in autoimmune type 1 diabetes mellitus(T1DM).Teplizumab,a humanized anti-CD3 monoclonal antibody,may help T1DM.Its long-term implications on clinical T1DM development,safety,and efficacy are unknown.AIM To assess the effectiveness and safety of teplizumab as a therapeutic intervention for individuals with T1DM.METHODS A systematic search was conducted using four electronic databases(PubMed,Embase,Scopus,and Cochrane Library)to select publications published in peerreviewed journals written in English.The odds ratio(OR)and risk ratio(RR)were calculated,along with their 95%CI.We assessed heterogeneity using Cochrane Q and I2 statistics and the appropriate P value.RESULTS There were 8 randomized controlled trials(RCTs)in the current meta-analysis with a total of 1908 T1DM patients from diverse age cohorts,with 1361 patients receiving Teplizumab and 547 patients receiving a placebo.Teplizumab was found to have a substantial link with a decrease in insulin consumption,with an OR of 4.13(95%CI:1.72 to 9.90).Teplizumab is associated with an improved Cpeptide response(OR 2.49;95%CI:1.62 to 3.81)and a significant change in Glycated haemoglobin A1c(HbA1c)levels in people with type 1 diabetes[OR 1.75(95%CI:1.03 to 2.98)],and it has a RR of 0.71(95%CI:0.53 to 0.95).CONCLUSION In type 1 diabetics,teplizumab decreased insulin consumption,improved C-peptide response,and significantly changed HbA1c levels with negligible side effects.Teplizumab appears to improve glycaemic control and diabetes management with good safety and efficacy. 展开更多
关键词 Type-1 diabetes mellitus Teplizumab Anti-CD3 monoclonal antibody INSUlIN Glycated haemoglobin A1c Cpeptide
下载PDF
Safety of teplizumab in patients with high-risk for diabetes mellitus type 1:A systematic review
6
作者 Venkata Buddhavarapu Gagandeep Dhillon +3 位作者 Harpreet Grewal Pranjal Sharma Rahul Kashyap Salim Surani 《World Journal of Diabetes》 SCIE 2024年第8期1793-1801,共9页
BACKGROUND The incidence of diabetes mellitus type 1(DM1)has been rising worldwide because of improvements in diagnostic techniques and improved access to care in countries with lower socioeconomic status.A new anti-C... BACKGROUND The incidence of diabetes mellitus type 1(DM1)has been rising worldwide because of improvements in diagnostic techniques and improved access to care in countries with lower socioeconomic status.A new anti-CD4 antibody,Teplizumab,has been shown to delay the progression of DM1 and is the only medication approved for this indication.However,more information is needed about the safety profile of this drug.AIM To identify the odds ratios(OR)of systems-based adverse effects for Teplizumab when compared to Placebo.METHODS An extensive systematic review was conducted from the inception of the medication until December 31,2023.All clinical trials and studies that evaluated Teplizumab vs placebo were included in the initial review.The study protocol was designed using Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines guidelines and was registered in PROSPERO(ID:CRD42024496169).Crude OR were generated using RevMan Software version 5.4.RESULTS After screening and review,5 studies were selected to determine the risk of adverse effects of teplizumab compared to placebo.A total of 561 patients were included in the study population.Total adverse effects and system-based adverse effects were studied and reported.We determined that patients receiving Teplizumab had a higher risk of developing gastrointestinal(GI)(OR=1.60,95%CI:1.01-2.52,P=0.04),dermatological(OR=6.33,95%CI:4.05-9.88,P<0.00001)and hematological adverse effects(OR=19.03,95%CI:11.09-32.66,P<0.00001).These patients were also significantly likely to have active Epstein-Barr Virus infection(OR=3.16,95%CI:1.51-6.64,P<0.002).While our data showed that patients receiving Teplizumab did have a higher incidence of total adverse effects vs placebo,this finding did not reach statistical significance(OR=2.25,95%CI:0.80-6.29,P=0.12).CONCLUSION Our systematic review suggests that Teplizumab patients are at risk for significant adverse effects,primarily related to GI,dermatological,and hematological systems.The total adverse effect data is limited as study populations are small.More studies should be conducted on this medication to better inform the target population of potential adverse effects. 展开更多
关键词 Teplizumab Diabetes mellitus type 1 Adverse effects monoclonal antibody Systematic review
下载PDF
靶向PD-1/PD-L1蛋白-蛋白相互作用小分子抑制剂研究进展 被引量:1
7
作者 宋伟 段学民 程建昕 《江西科学》 2024年第3期482-489,共8页
目的:阐述PD-1/PD-L1的相互作用机制及其在癌细胞免疫逃逸上的作用,并介绍近几年开发的靶向PD-1/PD-L1的新型小分子抑制剂。方法:检索国内外PD-1/PD-L1抑制剂的文献,整理和比较近几年开发的靶向PD-1/PD-L1的小分子抑制剂。结果:PD-1/PD... 目的:阐述PD-1/PD-L1的相互作用机制及其在癌细胞免疫逃逸上的作用,并介绍近几年开发的靶向PD-1/PD-L1的新型小分子抑制剂。方法:检索国内外PD-1/PD-L1抑制剂的文献,整理和比较近几年开发的靶向PD-1/PD-L1的小分子抑制剂。结果:PD-1/PD-L1抑制剂主要包括单克降抗体、拟肽抑制剂和小分子抑制剂,主要通过阻断PD-1/PD-L相互作用,形成PD-L1二聚体发挥作用。意义:开发靶向PD-1/PD-L1的小分子药物是一个具有挑战性的过程,小分子抑制剂具有比抗体更好的抑制肿瘤生长和迁移的能力,近几年小分子抑制剂的设计思路为小分子抑制剂的设计提供了新的思路。 展开更多
关键词 免疫逃逸 PD-1/PD-l1 单克隆抗体 小分子抑制剂
下载PDF
Application of VP1 Protein to Develop Monoclonal Antibody against Foot-and-mouth Disease Virus Asia1 Type 被引量:5
8
作者 Tong LIN Jun-zheng DU Jun-jun SHAO Guo-zheng CONG Shuai SONG Shan-dian GAO Hui-yun CHANG 《Virologica Sinica》 SCIE CAS CSCD 2009年第3期215-220,共6页
In order to develop an anti-FMDV Asial type monoclonal antibody (mAb), BABL/c mice were immunized with recombinant FMDV VP1 protein. Three mAbs, 1B8, 5El and 5E2, were then further optimized. The result indicated th... In order to develop an anti-FMDV Asial type monoclonal antibody (mAb), BABL/c mice were immunized with recombinant FMDV VP1 protein. Three mAbs, 1B8, 5El and 5E2, were then further optimized. The result indicated that prepared anti-FMDV Asial mAbs had no cross-reactivity with Swine vesicular disease (SVD) and FMDV O, A and C type antigen. Their titers in abdomen liquor were 1:5×10^6, 1:2×10^6 and 1:5×10^6, respectively. 1B8 was found to be of IgG1 subtype, 5El and 5E2 belonged to IgG2b subtype. In this study, the prepared mAbs are specific for detecting FMDV type Asia1, and is potentially useful for pen-side diagnosis. 展开更多
关键词 Asial type FMDV VP1 protein monoclonal antibody
下载PDF
Effects of monoclonal antibodies against human stathmin 1 combined paclitaxel on proliferation of human hepatocellular carcinoma cell lines 被引量:1
9
作者 ShuangWang Xiaoli Liu +3 位作者 Shaofei Yuan Wenjun Chen Senming Wang Na Xu 《The Chinese-German Journal of Clinical Oncology》 CAS 2009年第10期603-606,共4页
Objective: We investigated the effects of monoclonal antibodies against stathmin 1 combined paclitaxel on the proliferation of HCC cells. Methods: HepG2 cells were treated with monoclonal antibodies against stathmin... Objective: We investigated the effects of monoclonal antibodies against stathmin 1 combined paclitaxel on the proliferation of HCC cells. Methods: HepG2 cells were treated with monoclonal antibodies against stathmin 1, paclitaxel alone or their combination, with the untreated cells used as the control, 24, 48, 72, 96 h later, the cell growth condition was observed by invert microscope and inhabitation rate was studied by MTT assay; The apoptosis was analyzed by flow cytometry with Annexin V/PI. Results: The population decreased and shape, size changed after treating with different concentration of experimental groups. Monoclonal antibodies against stathmin 1 and paclitaxel used alone or in combination both inhibited the proliferation of HepG2 cells, the inhibition ratio of their combination was more higher (P 〈 0.05), and a synergistic effect of the two agents was noted in their combined action (P 〈 0.05). Combined treatment of the cells resulted in significantly higher apoptosis rate than that in the other groups (P 〈 0.05). Conclusion: Monoclonal antibodies against stathmin 1 and paclitaxel used alone or in combination both can inhibit proliferation of HepG2 cells and induce apoptosis. A synergistic effect is obsewed between the monoclonal antibodies against stathmin 1 and paclitaxel in their inhibition of HepG2 cell proliferation. 展开更多
关键词 hepatocellular carcinoma monoclonal antibodies against stathmin 1 PAClITAXEl PROlIFERATION apoptosis
下载PDF
Novel monoclonal antibody against beta 1 integrin enhances cisplatin efficacy in human lung adenocarcinoma cells
10
作者 Min-Young Kim Woon-Dong Cho +8 位作者 Kwon Pyo Hong Da Bin Choi Jeong won Hong Soseul Kim Yoo Ri Moon Seung-Myoung Son Ok-Jun Lee Ho-Chang Lee Hyung Geun Song 《The Journal of Biomedical Research》 CAS CSCD 2016年第3期217-224,共8页
The use of anti-beta 1 integrin monoclonal antibody in lung cancer treatment has proven beneficial. Here, we developed a novel monoclonal antibody (mAb), called P5, by immunizing mice with human peripheral blood mon... The use of anti-beta 1 integrin monoclonal antibody in lung cancer treatment has proven beneficial. Here, we developed a novel monoclonal antibody (mAb), called P5, by immunizing mice with human peripheral blood mononuclear cells (PBMC). Its anti-tumor effect is now being tested, in a clinical phase Ⅲ trial, in combinato- rial treatments with various chemical drugs. To confirm that P5 indeed binds to beta 1 integrin, cell lysates were immunoprecipitated with commercial anti-beta 1 integrin mAb (TS2/16) and immunoblotted against P5 to reveal a 140 kDa molecular weight band, as expected. Immunoprecipitation with P5 followed by LC/MS protein sequence analysis further verified P5 antigen to be beta 1 integrin. Cisplatin treatment upregulated cell surface expression of beta 1 integrin in A549 cells, while causing inhibition of cell growth. When cells were co-treated with different concentrations of P5 mAb, the cisplatin-mediated inhibitory effect was enhanced in a dose-dependent manner. Our findings show that a combinatorial treatment of P5 mAb and cisplatin in A549 cells resulted in a 30% increase in apoptosis, compared to baseline, and significantly more when compared to either the cisplatin or P5 alone group. The entire peptide sequences in CDR from variable region of Ig heavy and light chain gene for P5 mAb are also disclosed. Together, these results provide evidence of the beneficial effect of P5 mAb in combinatorial treatment of human lung adenocarcinoma. 展开更多
关键词 CD29 beta 1 integrin lung adenocarcinoma monoclonal antibody CISPlATIN
下载PDF
Induction of specific immunosuppression of cardiac allograft rejection withmonoclonal antibodies to CD44, LFA-1 and ICAM-1
11
作者 车小燕 罗爱武 +4 位作者 黄洪莲 周明乾 张亚莉 王小宁 郭亚军 《Journal of Medical Colleges of PLA(China)》 CAS 2000年第3期217-220,共4页
Objective:To evaluate the immunosuppressive effect of monoclonal antibodies (McAb) against cell surface adhesion molecules on transplant rejection. Methods: C57BL/6 (H-2b) mouse cardiac grafts were transplanted into B... Objective:To evaluate the immunosuppressive effect of monoclonal antibodies (McAb) against cell surface adhesion molecules on transplant rejection. Methods: C57BL/6 (H-2b) mouse cardiac grafts were transplanted into BALB/c(H- 2d) mice. This model was used to investigate the possibility of immunosuppressive induction with CD44 McAb, leukocyte function associated antigen (LFA-1) and intercellular adhesion molecule (ICAM-1). Results: Treatment of the allograft recipients with CD44 McAb alone, or both LFA-1 and ICAM-1 or combination of these 3 McAb significantly prolonged the cardiac allografts survival as compared with PBS controls (P<0.01). The combination of anti-CD44 and ICAM-1 and LFA-1 McAb was shown to produce more significant prolongation of grafts survival than anti-CD44 McAb alone or both anti-ICAM- 1 and LFA-1 McAb (P < 0.01). Histological examination of the grafts treated with the McAb displayed greatly reduced mononuclear cell infiltration. The proliferation of spleen cells from recipient BALB/c with McAb treatment was significantly inhibited in response to the stimulators of C57BL/6 spleen cells, but increased upon the stimulation of C3H/He (H-2k) spleen cells, as demonstrated by mixed lymphocyte reaction. Similarly, the cytotoxic activity against donor H-2-compatible (H-2b) target cells, EL-4 cells, was significantly suppressed. The spleen cells from allografted recipient BALB/c mice with McAb treatment induced specific tolerance for C57BL/6 cardiac grafts in allografted recipients, whereas those from allografted BALB/c mice without McAb treatment induced acute rejection. Conclusion: These results indicate that antiadhesion therapy using a combination of McAb to adhesion molecules can induce specific immunosuppression of transplant rejection. 展开更多
关键词 anti-CD44 anti-lFA-1 anti-ICAM-1 monoclonal antibody allograft REJECTION IMMUNOSUPPRESSION
下载PDF
Preparation and Characterization of Monoclonal Antibodies against VP1 Protein of Foot-and-mouth Disease Virus O/China99
12
作者 Shuai SONG Tong LIN +4 位作者 Jun-jun SHAO Shan-dian GAO Guo-zheng CONG Jun-zheng DU Hui-yun CHANG 《Virologica Sinica》 SCIE CAS CSCD 2009年第6期566-572,共7页
Monoclonal antibodies (McAbs) 1A9 and 9F12 against Foot-and-mouth disease virus (FMDV) serotype O were produced by fusing SP2/0 myeloma cells with splenocyte from the mouse immunized with O/China99. Both McAbs reacted... Monoclonal antibodies (McAbs) 1A9 and 9F12 against Foot-and-mouth disease virus (FMDV) serotype O were produced by fusing SP2/0 myeloma cells with splenocyte from the mouse immunized with O/China99. Both McAbs reacted with O/China99 but not with Asia 1, as determined by immunohistochemistry assay. The microneutralization titer of the McAbs 1A9 and 9F12 were 640 and 1 280, respectively. Both McAbs contain kappa light chains, but the McAbs 1A9 and 9F12 were IgG1 and IgM, respectively. In order to define the McAbs binding epitopes, the reactivity of these McAbs against VP1, P20 and P14 were examined using indirect ELISA, the result showed that both McAbs reacted with VP1 and P20. McAbs may be used for further studies of vaccine, diagnostic methods, prophylaxis, etiological and immunological researches on FMDV. 展开更多
关键词 Foot-and-mouth disease virus (FMDV) monoclonal antibody Neutralizing activity VP1 protein
下载PDF
Effects of anti-CXCR_4 monoclonal antibody 12G5 on proliferation and apoptosis of human acute myelocytic leukemia cell line HL-60
13
作者 魏立 孔佩艳 +6 位作者 史占忠 曾东风 陈幸华 常城 彭贤贵 张怡 刘红 《Journal of Medical Colleges of PLA(China)》 CAS 2007年第1期17-22,共6页
Objective:To investigate the expression of CXCR4 on HL-60 cell line and the proliferation, apoptosis of HL-60 cell line cocultured with bone marrow stromal cells, so as to assess the possibility of 12G5, an anti-CXCR... Objective:To investigate the expression of CXCR4 on HL-60 cell line and the proliferation, apoptosis of HL-60 cell line cocultured with bone marrow stromal cells, so as to assess the possibility of 12G5, an anti-CXCR4 monoclonal antibody, in eradicating the minimal residual disease. Methods:The activity of SDF-1 was inhibited by 10 μg/ml 12G5. After treatment with 12G5, the status of adhesion was observed, and the adhesion rates, apoptosis and cell cycles were detected after 24 h of treatment. Cell growth rates were measured by trypan blue exclusion. Cell growth curve was plotted, and the expression of PCNA and apoptosis related protein including PCNA, Bcl-2 and Fas were detected with immunohistochemical technique. Results:(1) There was middling degree expression of CXCR4 on HL-B0 membrane. From 0 h to 6 h, as the time of 12G5 incubation along, the expression of CXCR4 decreased gradually. (2) After treatment for 24 h, the adhesion rates in the experiment group and the control were (39.4±7.9)% and (51.4±5.9)%, respectively. (3)After treatment for 24 h, the percentage of HL-60 cells in G0/G1 phase were (55.21±4.9)%, and that in S phase and G2/M phase were (30.40±4.1)% and (14.39± 5.2)%, respectively, with the corresponding proportions being (44. 67±2.2)%, (45.30±3.7)%, and (10. 03±2.6)% in the control. (4) The percentage of apoptotic HL-60 cells was (8.95±1.7)% in the experiment group, compared to (3. 97±2. 4)% in the control. (5)The survival rates of HL-60 cells decreased markedly at 48 h to 96 h, and the proliferation slowed down at this time duration. (6)The expression of PCNA and Bcl-2 down-regulated significantly, but the Fas protein expression was up-regulated. Conclusion:12G5 could inhibit the capability of adhesion and proliferation of HL-60 cells and it can induce more cells to enter G0/G1 phase and promote apoptosis. It may be helpful by inhibiting the bioactivity of SDF-1 with 12G5 in the therapy of marrow residual disease. 展开更多
关键词 SDF-1/CXCR4 monoclonal antibody acute leukemia proliferation apoptosis drug resistance marrow residual disease
下载PDF
Production and characterisation of monoclonal antibodies specific to a conserv edepitope within hypervariable region1 of the hepatitis C virus
14
《中国输血杂志》 CAS CSCD 2001年第S1期346-,共1页
关键词 Production and characterisation of monoclonal antibodies specific to a conserv edepitope within hypervariable region1 of the hepatitis C virus
下载PDF
PD-1单抗后线辅助治疗晚期结直肠癌患者对胃肠功能、肿瘤标志物的影响 被引量:1
15
作者 吴翔 岳春迪 李春芸 《临床和实验医学杂志》 2024年第9期941-945,共5页
目的分析程序性死亡受体-1(PD-1)单抗后线辅助治疗晚期结直肠癌患者对胃肠功能、肿瘤标志物的影响。方法前瞻性选取2020年1月至2023年1月海口市人民医院收治的105例晚期结直肠癌患者为研究对象,按照随机数字表法将患者分为对照组(n=50)... 目的分析程序性死亡受体-1(PD-1)单抗后线辅助治疗晚期结直肠癌患者对胃肠功能、肿瘤标志物的影响。方法前瞻性选取2020年1月至2023年1月海口市人民医院收治的105例晚期结直肠癌患者为研究对象,按照随机数字表法将患者分为对照组(n=50)、研究组(n=55)。对照组采用阿帕替尼治疗,研究组在对照组的基础上联合PD-1单抗后线治疗,3周为1个疗程,共治疗4个疗程。比较两组的临床疗效、胃肠功能改善时间,治疗前、治疗12周后的肿瘤标志物[癌胚抗原、糖类抗原(CA)72-4、CA199]、免疫功能(CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))指标以及不良反应发生情况。结果治疗12周后,研究组的客观缓解率(ORR)、病情控制率(DCR)分别为78.33%、90.91%,均高于对照组(58.00%、70.00%),差异均有统计学意义(P<0.05)。研究组患者的首次排便时间、首次排气时间、肠鸣音消退时间分别为(51.50±5.02)、(35.52±4.25)、(44.28±4.80)d,均短于对照组[(69.37±6.40)、(50.63±5.10)、(53.50±6.15)d],差异均有统计学意义(P<0.05)。治疗12周后,研究组癌胚抗原、CA72-4、CA199水平分别为(12.57±1.64)ng/mL、(17.60±3.45)U/mL、(58.29±8.70)kU/L,均低于对照组[(17.24±2.50)ng/mL、(27.59±4.67)U/mL、(82.65±12.29)kU/L],差异均有统计学意义(P<0.05)。治疗12周后,研究组CD4^(+)、CD4^(+)/CD8^(+)水平分别为(21.42±3.54)%、0.73±0.30,均低于对照组[(28.39±4.38)%、1.12±0.41],CD8^(+)水平为(30.36±4.52)%,高于对照组[(25.71±3.30)%],差异均有统计学意义(P<0.05)。研究组的不良反应发生率为9.09%,稍低于对照组(16.00%),但两组比较差异无统计学意义(P>0.05)。结论通过PD-1单抗后线辅助治疗可有效改善晚期结直肠癌患者的临床疗效,效果明显,改善胃肠功能,降低肿瘤标志物指标水平,调节机体免疫功能,可为临床干预此病提供参考。 展开更多
关键词 结直肠肿瘤 晚期结直肠癌 程序性死亡受体-1单抗 胃肠功能 肿瘤标志物
下载PDF
Efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy in treatment of advanced gastric cancer or gastroesophageal junction cancer: A meta-analysis 被引量:4
16
作者 Li Yang Xian-Zhe Dong +3 位作者 Xiao-Xuan Xing Xiao-Hui Cui Lin Li Lan Zhang 《World Journal of Gastrointestinal Oncology》 SCIE CAS 2020年第11期1346-1363,共18页
BACKGROUND Faced with limited and inadequate treatment options for patients with advanced gastric cancer or gastroesophageal junction cancer(GC/GEJC), researchers have turned toward, with the support of promising clin... BACKGROUND Faced with limited and inadequate treatment options for patients with advanced gastric cancer or gastroesophageal junction cancer(GC/GEJC), researchers have turned toward, with the support of promising clinical trials, anti-PD-1/anti-PD-L1 antibody therapy. But there are also different clinical trial results. To better assess its efficacy and safety, we integrated data from 13 eligible studies for a systematic review and meta-analysis.AIM To comprehensively evaluate the efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy in the treatment of advanced GC/GEJC patients.METHODS PubMed, Web of Science, Cochrane Library,and EMBASE databases were searched to identify eligible articles with outcomes including objective response rate(ORR), disease control rate(DCR), overall survival(OS), progression-free survival(PFS), and adverse events(AEs) of anti-PD-1/anti-PD-L1 antibody therapy.RESULTS Our study encompassed a total of 13 trials totaling 1618 patients. The outcomes showed a pooled ORR and DCR of 15%(95% confidence interval [CI]: 14%-18%) and 40%(95%CI: 33%-46%), respectively. The pooled 6-mo OS and PFS were 54%(95%CI: 45%-64%) and 26%(95%CI: 20%-32%), respectively, and the 12-mo OS and PFS were 42%(95%CI: 21%-62%) and 11%(95%CI: 8%-13%), respectively. In addition, the incidence of any-grade AEs and grade ≥ 3 AEs was 64%(95%CI: 54%-73%) and 18%(95%CI: 16%-20%), respectively. Most importantly, PD-L1 positive patients exhibited a higher ORR rate than PD-L1 negative patients(odds ratio = 2.54, 95%CI: 1.56-4.15).CONCLUSION Anti-PD-1/anti-PD-L1 antibody therapy has shown promising anti-tumor efficacy with manageable AEs in advanced GC/GEJC patients, with PD-L1 overexpressing patients exhibiting a higher ORR. What is more, the clinical efficacy of anti-PD-1/PD-L1 combined with traditional chemotherapy drugs is even better, although the occurrence of AEs still causes considerate concerns. 展开更多
关键词 Gastric cancer Gastroesophageal junction cancer anti-pd-1/anti-pd-l1 antibody therapy META-ANAlYSIS Systematic review
下载PDF
靶向骨肉瘤PD-1/PD-L1信号通路探针的实验研究
17
作者 黄海峰 邹欢 +3 位作者 王炼 杨先腾 朱华 李姗姗 《安徽医科大学学报》 CAS 北大核心 2023年第11期1823-1827,共5页
目的探讨筛选程序性死亡受体-1(PD-1)/程序性死亡受体配体-1(PD-L1)信号通路表达阳性的骨肉瘤患者的无创检测手段。方法通过瘤块成瘤方法建立人骨肉瘤细胞(OS-732)皮下荷瘤鼠动物模型,毒性试验验证PD-L1抗体对小鼠脏器的毒性,进一步合成... 目的探讨筛选程序性死亡受体-1(PD-1)/程序性死亡受体配体-1(PD-L1)信号通路表达阳性的骨肉瘤患者的无创检测手段。方法通过瘤块成瘤方法建立人骨肉瘤细胞(OS-732)皮下荷瘤鼠动物模型,毒性试验验证PD-L1抗体对小鼠脏器的毒性,进一步合成124 I-anti-PD-L1单克隆抗体分子探针,在OS-732荷瘤鼠尾静脉注射18.5 MBq 124 I-anti-PD-L1探针开始进行OS-732骨肉瘤的微型正电子发射断层显像/计算机断层成像(Micro-PET/CT)显像。结果OS-732骨肉瘤模型成功构建,免疫组化显示OS-732骨肉瘤存在PD-L1蛋白的表达,Micro-PET/CT在不同的时间点(注射探针后2、24、48 h)成功显像OS-732骨肉瘤,实现对骨肉瘤PD-L1的无创实时观测。结论124 I-anti-PD-L1单克隆抗体分子探针可以成功靶向OS-732骨肉瘤的PD-L1受体,并呈现清晰的免疫成像,从而实现无创筛选PD-L1阳性表达的骨肉瘤患者。 展开更多
关键词 骨肉瘤 PD-1 PD-l1 PET/CT 单克隆抗体 免疫检查点
下载PDF
犬PD-1单克隆抗体的筛选与鉴定
18
作者 王卓 徐司雨 +8 位作者 夏兴霞 李志敏 毕振威 钱晶 莫菲 诸玉梅 王永山 孙树民 谭业平 《中国兽药杂志》 2024年第5期10-16,共7页
为筛选犬程序性死亡受体1(cPD-1)单克隆抗体,以原核表达并纯化复性的cPD-1胞外区蛋白为靶抗原免疫BALB/c小鼠,应用单克隆抗体杂交瘤细胞技术和间接ELISA方法,经3轮轮筛选和克隆化,获得1株能稳定分泌抗cPD-1单克隆抗体的杂交瘤细胞株1F9... 为筛选犬程序性死亡受体1(cPD-1)单克隆抗体,以原核表达并纯化复性的cPD-1胞外区蛋白为靶抗原免疫BALB/c小鼠,应用单克隆抗体杂交瘤细胞技术和间接ELISA方法,经3轮轮筛选和克隆化,获得1株能稳定分泌抗cPD-1单克隆抗体的杂交瘤细胞株1F9。间接ELISA检测显示1F9杂交瘤细胞株连续传代培养能稳定分泌单克隆抗体,效价达到1∶2048,亚型鉴定重链为IgG1,轻链为κ;以HEK293细胞表达cPD-1胞外区蛋白为检测抗原,Western-blot和间接免疫荧光试验进行鉴定,结果显示1F9单克隆抗体能特异性结合cPD-1胞外区蛋白。本研究通过小鼠杂交瘤技术成功筛选到1株鼠源cPD-1单克隆抗体。 展开更多
关键词 PD-1 单克隆抗体 肿瘤
下载PDF
PD-1单抗治疗一例dMMR/MSI-H/TMB-H型结肠癌伴颅内转移瘤患者临床完全缓解
19
作者 项涛 张航瑜 +1 位作者 方维佳 陈文斌 《浙江大学学报(医学版)》 CAS CSCD 北大核心 2024年第1期58-63,共6页
一例70岁男性患者,在接受右半肠癌根治性手术1年后出现了记忆丧失和认知功能下降的症状,头颅磁共振成像检查发现脑部肿块,手术后经病理检查确诊为结肠腺癌转移。原发灶及颅内转移瘤免疫组织化学检测均提示为错配修复缺陷。原发结肠肿瘤... 一例70岁男性患者,在接受右半肠癌根治性手术1年后出现了记忆丧失和认知功能下降的症状,头颅磁共振成像检查发现脑部肿块,手术后经病理检查确诊为结肠腺癌转移。原发灶及颅内转移瘤免疫组织化学检测均提示为错配修复缺陷。原发结肠肿瘤组织基因检测证实为微卫星高度不稳定伴有高肿瘤突变负荷,肿瘤突变负荷为77.7 muts/Mb。患者结肠癌根治术和颅内转移瘤术后均接受了辅助化疗,但在颅内转移瘤切除术和化疗结束后1个月颅内转移复发。患者接受帕博利珠单抗治疗后结果颅内转移瘤消退并达到临床完全缓解。 展开更多
关键词 肠癌 微卫星高度不稳定 高肿瘤突变负荷 脑转移 程序性死亡受体1单抗 病例报告
下载PDF
PD-1单抗联合化疗在食管癌治疗中的有效性及安全性分析
20
作者 申晓梅 薛锦 刘兴祥 《中国医药科学》 2024年第20期144-147,共4页
目的探讨程序性死亡受体1(PD-1)单抗联合化疗在食管癌治疗中的有效性及安全性。方法选择2022年1月至2023年12月泰州市第二人民医院收治的80例食管癌患者为研究对象,按照随机数表法分为研究组与对照组,每组各40例。对照组患者给予紫杉醇... 目的探讨程序性死亡受体1(PD-1)单抗联合化疗在食管癌治疗中的有效性及安全性。方法选择2022年1月至2023年12月泰州市第二人民医院收治的80例食管癌患者为研究对象,按照随机数表法分为研究组与对照组,每组各40例。对照组患者给予紫杉醇(白蛋白结合型)+顺铂化疗,研究组患者给予PD-1单抗联合紫杉醇(白蛋白结合型)+顺铂化疗。比较两组患者PD-1、程序性死亡-配体1(PD-L1)水平,免疫功能指标(CD3~+、CD4~+、CD4~+/CD8~+),临床疗效以及不良反应总发生率。结果研究组患者PD-1、PD-L1水平明显低于对照组,差异有统计学意义(P<0.05);研究组患者免疫功能指标明显高于对照组,差异有统计学意义(P<0.05);研究组患者治疗总有效率明显高于对照组,差异有统计学意义(P<0.05);研究组患者不良反应总发生率明显低于对照组,差异有统计学意义(P<0.05)。结论采用PD-1单抗联合紫杉醇+顺铂化疗能够有效提升食管癌患者临床疗效与免疫功能,并降低患者PD-1、PD-L1水平和不良反应发生率,值得推广应用。 展开更多
关键词 PD-1单抗 紫杉醇(白蛋白结合型) 顺铂 食管癌 有效性 安全性
下载PDF
上一页 1 2 18 下一页 到第
使用帮助 返回顶部